RANK (TNFRSF11A) is Epigenetically Inactivated and induces apoptosis in gliomas

Neoplasia (United States)

Volumn 14, Issue 6, 2012, Pages 526-534

  von dem Knesebeck, Anna ^a   Felsberg, Jörg ^b   Waha, Anke ^a   Hartmann, Wolfgang ^c   Scheffler, Björn ^a   Glas, Martin ^a   Hammes, Jennifer ^a   Mikeska, Thomas ^a   Yan, Pearlly S ^d   Endl, Elmar ^a   Simon, Matthias ^a   Reifenberger, Guido ^b   Pietsch, Torsten ^a   Waha, Andreas ^a  

^a UNIVERSITY OF BONN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; ASTROCYTOMA; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84865624175     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1596/neo.12360     Document Type: Article

References (41)

1. TCGA (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
2. Ohgaki H and Kleihues P (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170, 1445-1453.
3. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812.
4. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med 360, 765-773.
5. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522.
6. Waha A, Rodrigues F, Waha A, Meyer-Puttlitz B, Cavenee W, Huang T-M, and Yan P (2004). Methylation profiling identifies epigenetic markers for high-grade gliomas. Cancer Genomics Proteomics 1, 209-214.
7. Darnay BG, Besse A, Poblenz AT, Lamothe B, and Jacoby JJ (2007). TRAFs in RANK signaling. Adv Exp Med Biol 597, 152-159.
8. Teitelbaum SL and Ross FP (2003). Genetic regulation of osteoclast development and function. Nat Rev Genet 4, 638-649.
9. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, and Heymann D (2004). The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15, 457-475.
10. Bharti AC, Takada Y, Shishodia S, and Aggarwal BB (2004). Evidence that receptor activator of nuclear factor (NF)-?B ligand can suppress cell proliferation and induce apoptosis through activation of a NF-?B-independent and TRAF6-dependent mechanism. J Biol Chem 279, 6065-6076.
11. Müller I, Pfister SM, Grohs U, Zweigner J, Handgretinger R, Niethammer D, and Bruchelt G (2003). Receptor activator of nuclear factor?B ligand plays a nonredundant role in doxorubicin-induced apoptosis. Cancer Res 63, 1772-1775.
12. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, and Kleihues P (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97-109.
13. Ichimura K, Schmidt EE, Goike HM, and Collins VP (1996). Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13, 1065-1072.
14. Glas M, Rath BH, Simon M, Reinartz R, Schramme A, Trageser D, Eisenreich R, Leinhaas A, Keller M, Schildhaus HU, et al. (2010). Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol 68, 264-269.
15. Yan PS, Chen CM, Shi H, Rahmatpanah F, Wei SH, Caldwell CW, and Huang TH (2001). Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 61, 8375-8380.
16. Waha A, Guntner S, Huang TH, Yan PS, Arslan B, Pietsch T, Wiestler OD, and Waha A (2005). Epigenetic silencing of the protocadherin family member PCDH-?-A11 in astrocytomas. Neoplasia 7, 193-199.
17. Eisenberg E and Levanon EY (2003). Human housekeeping genes are compact. Trends Genet 19, 362-365.
18. Hartmann W, Kuchler J, Koch A, Friedrichs N, Waha A, Endl E, Czerwitzki J, Metzger D, Steiner S, Wurst P, et al. (2009). Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 15, 4538-4545.
19. Waha A, Felsberg J, Hartmann W, von dem Knesebeck A, Mikeska T, Joos S, Wolter M, Koch A, Yan PS, Endl E, et al. (2010). Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res 70, 1689-1699.
20. Friedrichs N, Kuchler J, Endl E, Koch A, Czerwitzki J, Wurst P, Metzger D, Schulte JH, Holst MI, Heukamp LC, et al. (2008). Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 216, 428-439.
21. Friedrichs N, Trautmann M, Endl E, Sievers E, Kindler D, Wurst P, Czerwitzki J, Steiner S, Renner M, Penzel R, et al. (2011). Phosphatidylinositol-3'-kinase/ AKT signaling is essential in synovial sarcoma. Int J Cancer 129, 1564-1575.
22. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, and Poirier GG (1993). Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53, 3976-3985.
23. Sherf BA, Navarro SL, Hannah RR, and Wood KV (1996). Dual-luciferase reporter assay: an advanced co-reporter technology integrating firefly and Renilla luciferase assays. Promega Notes 57, 2-8.
24. Bharti AC and Aggarwal BB (2004). Ranking the role of RANK ligand in apoptosis. Apoptosis 9, 677-690.
25. Min JK, Kim YM, Kim EC, Gho YS, Kang IJ, Lee SY, Kong YY, and Kwon YG (2003). Vascular endothelial growth factor up-regulates expression of receptor activator of NF-? B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 278, 39548-39557.
26. Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, Trichereau J, Paolino M, Qadri F, Plehm R, et al. (2009). Central control of fever and female body temperature by RANKL/RANK. Nature 462, 505-509.
27. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, and Gillespie MT (1999). Localization of RANKL (receptor activator of NF?B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25, 525-534.
28. Serrano EM, Ricofort RD, Zuo J, Ochotny N, Manolson MF, and Holliday LS (2009). Regulation of vacuolar H(+)-ATPase in microglia by RANKL. Biochem Biophys Res Commun 389, 193-197.
29. Ito R, Nakayama H, Yoshida K, Kuraoka K, Motoshita J, Oda N, Oue N, and Yasui W (2003). Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch 443, 146-151.
30. Naumann U, Wick W, Beschorner R, Meyermann R, and Weller M (2004). Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol 107, 17-22.
31. Gingery A, Bradley E, Shaw A, and Oursler MJ (2003). Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NF?B pathways to maintain osteoclast survival. J Cell Biochem 89, 165-179.
32. Sugatani T, Alvarez U, and Hruska KA (2003). PTEN regulates RANKL-and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem 278, 5001-5008.
33. Darnay BG, Haridas V, Ni J, Moore PA, and Aggarwal BB (1998). Characterization of the intracellular domain of receptor activator of NF-?B (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-?B and c-Jun N-terminal kinase. J Biol Chem 273, 20551-20555.
34. Galibert L, Tometsko ME, Anderson DM, Cosman D, and Dougall WC (1998). The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-?B, a member of the TNFR superfamily. J Biol Chem 273, 34120-34127.
35. Kim HH, Lee DE, Shin JN, Lee YS, Jeon YM, Chung CH, Ni J, Kwon BS, and Lee ZH (1999). Receptor activator of NF-?B recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 443, 297-302.
36. Martinet W, De Meyer GR, Herman AG, and Kockx MM (2005). Amino acid deprivation induces both apoptosis and autophagy in murine C2C12 muscle cells. Biotechnol Lett 27, 1157-1163.
37. Liu Y, Li C, and Lin J (2010). STAT3 as a therapeutic target for glioblastoma. Anticancer Agents Med Chem 10, 512-519.
38. Natsume A, Kinjo S, Yuki K, Kato T, Ohno M, Motomura K, Iwami K, and Wakabayashi T (2011). Glioma-initiating cells and molecular pathology: implications for therapy. Brain Tumor Pathol 28, 1-12.
39. Li GH, Wei H, Lv SQ, Ji H, and Wang DL (2010). Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. Int J Oncol 37, 103-110.
40. Sherry MM, Reeves A, Wu JK, and Cochran BH (2009). STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27, 2383-2392.
41. Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, and Yu H (2010). Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 8, 35-45.